Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

Core Viewpoint - Mersana Therapeutics is implementing a strategic restructuring and reprioritization plan to extend its cash runway and focus on the development of its lead product, emiltatug ledadotin (Emi-Le), targeting cancers with high unmet medical needs [1][2] Group 1: Strategic Restructuring - The company will reduce its workforce by approximately 55% across functions, with the reduction expected to be substantially complete by the end of Q3 2025 [2][4] - Mersana will also cut research activities and eliminate internal pipeline development efforts, focusing on Emi-Le development for breast cancer to gather additional safety and clinical activity data [3][9] Group 2: Financial Outlook - The actions taken are expected to provide sufficient cash resources to support the company's operating plan commitments into mid-2026 [4][8] - Mersana plans to announce its financial results for Q1 2025 on May 15, 2025, and will host a conference call to discuss business updates [5][8] Group 3: Product Pipeline - Mersana's pipeline includes Emi-Le (XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of HER2 [6]